Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial

Published:2017-11 Issue:2 Volume:125 Page:223-227
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Møller Søren,Munck af Rosenschöld Per,Costa Junia,Law Ian,Poulsen Hans Skovgaard,Engelholm Svend Aage,Engelholm Silke

Funder

Capital Region of Denmark

Lundbeck Foundation

Aalborg University Hospital

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference26 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

2. ESTRO-ACROP guideline “target delineation of glioblastomas”;Niyazi;Radiother Oncol,2016

3. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Stupp;Ann Oncol,2014

4. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas;Fogh;J Clin Oncol,2010

5. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution;Combs;J Clin Oncol,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence;Journal of Personalized Medicine;2024-05-17

2. Treatment advances in high-grade gliomas;Frontiers in Oncology;2024-04-10

3. Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck;Radiation Oncology Journal;2024-03-31

4. Re-irradiation combined with bevacizumab in the treatment of glioblastoma recurrence;Siberian journal of oncology;2024-03-21

5. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors;Scientific Reports;2023-06-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3